Planet Labs R&D increased by 17.8% to $32.19M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 40.3%, from $22.95M to $32.19M. Over 4 years (FY 2022 to FY 2026), R&D shows an upward trend with a 12.5% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $12.13M | $12.43M | $14.96M | $27.16M | $24.75M | $26.74M | $27.60M | $31.83M | $28.19M | $26.74M | $33.00M | $28.41M | $25.59M | $27.25M | $25.22M | $22.95M | $23.07M | $24.16M | $27.33M | $32.19M |
| QoQ Change | — | +2.5% | +20.3% | +81.6% | -8.9% | +8.0% | +3.2% | +15.3% | -11.5% | -5.1% | +23.4% | -13.9% | -9.9% | +6.5% | -7.5% | -9.0% | +0.5% | +4.7% | +13.1% | +17.8% |
| YoY Change | — | — | — | — | +104.0% | +115.1% | +84.5% | +17.2% | +13.9% | +0.0% | +19.6% | -10.7% | -9.2% | +1.9% | -23.6% | -19.2% | -9.8% | -11.4% | +8.4% | +40.3% |
| Segment | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $20.84M | $20.84M | $20.84M | $20.84M | $18.86M | $18.99M | $17.38M | $18.38M |
| Total | $28.19M | $26.74M | $33.00M | $28.41M | $25.59M | $27.25M | $23.07M | $24.16M |
Reportable Segment was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.